title: Ophthalmic manifestations of HIV: an update.
abstract: A variety of ocular disease processes have been identified in HIV-antibody positive persons, especially in people with AIDS. The most common sight-threatening disease in this population is cytomegalovirus (CMV) retinitis. Effective therapies are available to treat CMV retinitis. However, such therapies carry potentially challenging toxicities. Highly active antiretroviral therapy (HAART) has improved immune system functioning in many of its adherents, decreasing the incidence and improving the clinical course of CMV retinitis. However, a recent phenomenon associated with HAART, immune recovery uveitis (IRU), has been noted with additional, often problematic ocular manifestations in many persons with CMV retinitis. Periodic ophthalmic examination is prudent for all persons with HIV and especially for people with AIDS.
authors.forename: M G
authors.initials: MG
authors.lastname: DeGrezia
authors.forename: M
authors.initials: M
authors.lastname: Robinson
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000451:nursing / Q000628:therapy*; D000284:Administration, Oral; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017726:Cytomegalovirus Retinitis / Q000451:nursing / Q000628:therapy*; D006801:Humans; D007267:Injections; D014605:Uveitis / Q000139:chemically induced* / Q000451:nursing
chemical_list: D000998:Antiviral Agents